Drug Database
TE

telmisartan + amlodipine (Micamlo BP / Onduarp / Micamlo AP)

✓ Approved

Astellas Pharma · AGTR1 · Small Molecule

What is telmisartan + amlodipine?

telmisartan + amlodipine is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesMicamlo BP, Onduarp, Micamlo AP
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetAGTR1, CACNA1C
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Astellas Pharma

Mechanism of Action

Molecular Targets

telmisartan + amlodipine acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

telmisartan + amlodipine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedJournal of colloid and interface science2026-07-17

Synergistic catalysis on Sn-Bi heterostructures for highly selective electrosynthesis of glycine.

Tan Jing J, Jin Xixiong X, Wei Zixuan Z, Chen Weiren W et al.

Electrocatalytic co-reduction of abundant carbon and nitrogen feedstocks opens a promising route for the sustainable production of amino acids. However, mismatched reduction rates between carbon and nitrogen sources and the sluggish reaction kinetics remain great challenges preventing its practical application. Herein, we report synergistic catalysis over Sn-Bi heterostructures for highly selective electrosynthesis of glycine from oxalic acid and nitrate. The optimal Sn-Bi/C catalyst exhibits a high glycine Faradaic efficiency of 79.7%, a partial current density of 163.7 mA cm-2, and a carbon selectivity of 80.2%, enabling gram-scale production of glycine in a long-term electrolysis. Mechanistically, Sn sites accelerate nitrate reduction to hydroxylamine, Bi sites drive oxalic acid reduction to glyoxylic acid, and the Sn-Bi interfaces favor the reduction of glyoxylic acid oxime to glycine. The interfacial electron transfer between Sn and Bi modifies the p-band center, thereby regulating the adsorption behavior of key intermediates during the reduction of glyoxylic acid oxime. By precisely coordinating the site-specific reduction of nitrate and oxalic acid on Sn and Bi sites, respectively, the formation rates of the key C- and N-containing intermediates are kinetically matched. This synergistic catalytic strategy significantly enhances C-N coupling efficiency and accelerates glycine formation kinetics, thereby establishing a new design paradigm for electrocatalysts toward controllable C-N coupling.

PMID 42462668
Read full article →
PubMedTelemedicine journal and e-health : the official journal of the American Telemedicine Association2026-07-17

Preparing Medical Students for Virtual Care: Perceptions of Adoption.

Holtz Bree B, Ford Sabrina S, Iddrisu Naadiyahtu N, Wendling Andrea A et al.

As telemedicine becomes an integral component of health care delivery, understanding factors that influence medical students' acceptance of this technology is essential. This study explores medical students' perceptions of telemedicine adoption using the Unified Theory of Acceptance and Use of Technology (UTAUT) framework. A cross-sectional survey of 98 medical students assessed telemedicine perceptions across UTAUT constructs: performance expectancy (PE), effort expectancy (EE), facilitating conditions (FC), social influence (SI), and behavioral intention (BI). Open-ended responses were thematically analyzed using a deductive approach to contextualize quantitative findings. PE was the strongest predictor of BI to use telemedicine among medical students (B = 0.771, p < 0.001), whereas EE, SI, and FC were not significant predictors. Qualitative responses reinforced telemedicine's perceived value, particularly for improving access to care and shaping future health care delivery, while highlighting limited formal training and a desire for more structured learning opportunities. These findings support integrating structured telemedicine training, experiential learning, and mentorship into medical curricula to enhance readiness for delivering technology-enabled care.

PMID 42466585
Read full article →
PubMedFrontiers in neurology2026-07-17

Comparing the real-world effectiveness of botulinum toxin type A injections across distinct poststroke muscle hyper-resistance patterns.

Liu Xuncan X, Chen Chen C, Ju Yanmin Y, Zhao Liang L et al.

Post-stroke muscle hyper-resistance is produced by both neurogenic (spasticity) and non-neurogenic (contracture) factors. BoNT-A is the most effective intervention for post-stroke spasticity, yet whether concomitant contracture alters its therapeutic benefit remains unclear. To compare BoNT-A effectiveness in plantar-flexor hyper-resistance stratified by contracture. We retrospectively reviewed stroke survivors with spastic hemiplegia and ankle plantar-flexor hyper-resistance who received BoNT-A injections. Patients were stratified into two groups according to the presence of restricted passive ankle dorsiflexion: the spasticity group (PROM limitation <7°) and the spasticity-with-contracture group (PROM limitation ≥7°). Outcomes were assessed at baseline and at 2, 4 and 12 weeks post-injection, including the Modified Ashworth Scale (MAS) for plantar-flexors, Brunnstrom Recovery Stage (BRS), Fugl-Meyer Assessment (FMA) lower-extremity subscore and Barthel Index (BI). A total of 107 patients were enrolled-54 in the spasticity group and 53 in the spasticity-with-contracture group. Baseline comparison revealed a significantly longer disease duration in the spasticity-with-contracture group; other characteristics were comparable. Both groups achieved improvements in MAS and BRS at all three follow-up visits. FMA and BI improved in the spasticity group at 4 and 12 weeks, whereas the spasticity-with-contracture group showed improvement only at 12 weeks. Between-group analyses indicated that MAS and BRS scores were consistently better in the spasticity group at each time point; although median FMA and BI were numerically higher in this group, the differences did not reach statistical significance. BoNT-A markedly reduces post-stroke hyper-resistance and enhances motor function and activities of daily living; by contrast, concomitant contracture is associated with delayed and attenuated improvement in MAS and BRS.

PMID 42465548
Read full article →
PubMedCancer research2026-07-17

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity.

Mårtensson Linda L, Holmkvist Petra P, Cleary Kirstie L KL, Svensson Carolin C et al.

Although checkpoint inhibitors have revolutionized cancer treatment, responses are largely restricted to targeting CTLA-4 and PD-(L)1. TNFR2 has been identified as a promising target, but further therapeutic development requires a better understanding of whether agonists or blockers should be used and whether FcγR interactions promote efficacy. Here, we engineered two distinct α-TNFR2 antibody types: ligand-blocking FcγR-engaging versus non-ligand-blocking agonist antibodies. Both showed potent anti-tumor efficacy across multiple syngeneic mouse tumor models and combined effectively with α-PD-1. The ligand-blocking antibody depleted intratumoral Tregs and reprogrammed the myeloid compartment, directing monocytes towards a pro-inflammatory macrophage and dendritic cell trajectory. Interestingly, this effect depended on both inhibitory and activating FcγRs, reflecting the simultaneous action on Tregs and myeloid cells. In contrast, the agonist directly co-stimulated T and NK cells, partially through FcγR-independent mechanisms. Both antibodies converged on activating tumor-specific CD8+ T cells mediating tumor rejection. Clinical assessment of both ligand-blocking (BI-1808) and agonist (BI-1910) α-TNFR2 antibodies is currently ongoing.

PMID 42466984
Read full article →
PubMedScientific reports2026-07-17

Research on forward-looking sonar target detection algorithm based on edge enhancement and multi-scale feature fusion.

Xiao Yonglin Y, Shuai Changgeng C, Li Buyun B, Yuan Chengren C et al.

Forward-looking sonar (FLS) images suffer from low resolution, severe noise interference, and limited discriminability of small targets, posing significant challenges for underwater object detection. To address these issues, this paper proposes ESBN-YOLO, a detection framework built upon YOLOv11 with three key improvements. First, an Efficient Multi-scale Bi-directional Feature Pyramid Network (EMBSFPN-SC) is designed, which leverages a three-round bi-directional fusion strategy coupled with a zero-parameter spatial channel enhancement mechanism to strengthen multi-scale feature representation. Second, an Edge Information Enhancement Module (EIEM) is introduced, adopting a dual-branch architecture that fuses Sobel-based explicit edge features with deep semantic features, thereby sharpening the model's sensitivity to object boundaries in noisy sonar imagery. Third, the Normalized Wasserstein Distance (NWD) loss is combined with CIoU as a weighted-sum bounding-box regression loss, replacing the original IoU-only formulation, yielding improved recall and localization accuracy for small targets. Experiments on the UATD dataset demonstrate that ESBN-YOLO achieves an mAP@0.5 of 88.67%, outperforming all compared methods. Additional evaluations on the MDD and FDD datasets further confirm the generalization capability and practical applicability of the proposed approach.

PMID 42463503
Read full article →
PubMedFrontiers in neurology2026-07-17

Early emotional interventions for post-stroke functional prognosis: a systematic review and meta-analysis.

Xiao Ying Y, Huang Bin B, Liu Qin Q, Du Huan H

Post-stroke emotional disorders (PSEDs) impair functional recovery, but the optimal type and timing of early interventions remain unclear. This study aimed to determine the efficacy of early emotional interventions on functional outcomes in stroke patients and to examine whether benefits differ by intervention type and timing of initiation. In this systematic review and meta-analysis, we searched seven databases for randomized controlled trials (RCTs) up to November 2025. We included adults with acute/subacute stroke (≤ 3 months) assigned to an emotional intervention (pharmacological, psychological, neuromodulation, or combined) versus control. The primary outcome was the change in Barthel Index (BI) at follow-up. Thirty-eight RCTs (n = 12,020 participants) were included. The weighted mean difference (WMD) in BI score improvement was 6.8 (95% CI: 5.2-8.4) favoring interventions over control. The WMD was 8.2 (95% CI: 5.7-10.7) for cognitive behavioral therapy [k = 12], 9.1 (95% CI: 6.5-11.7) for combined interventions [k = 5], 6.5 (95% CI: 4.1-8.9) for rTMS [k = 7], and 4.2 (95% CI: 1.8-6.6) for SSRIs [k = 14]. Initiation of intervention within 2 weeks post-stroke yielded a greater WMD of 10.3 (95% CI: 7.8-12.8) compared to 5.8 (95% CI: 3.6-8.0) for later initiation (p < 0.01). Early emotional interventions significantly improve functional recovery after stroke, with the greatest benefit observed for cognitive behavioral therapy and combined interventions initiated within 2 weeks of stroke onset. These findings support the integration of targeted emotional interventions into early standard care.

PMID 42465544
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about telmisartan + amlodipine